Revenues from operations grew by 11 per cent to Rs 4,336 crore during the quarter under discussion against Rs 3,906 crore in Q3 of last fiscal.
N. Govindarajan, managing director of the company said, "All our key markets continue to perform well and have shown a healthy growth trend. Consideringthe one-off US tax charge, the profitability is in-line with our expectations. We continue to invest in enhancing our specialty and complex generics pipeline, for a sustainable growth."
The Active Pharmaceuticals Ingredients (API) business contributed 18 per cent to the total revenue and posted a sales of Rs 765.7 crore in the third quarter.